Analysts Have Conflicting Sentiments on These Healthcare Companies: Kamada (NASDAQ: KMDA), Perrigo Company (NYSE: PRGO) and Eli Lilly & Co (NYSE: LLY)By Ryan Adsit
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Kamada (NASDAQ: KMDA), Perrigo Company (NYSE: PRGO) and Eli Lilly & Co (NYSE: LLY).
Kamada (NASDAQ: KMDA)
In a report released yesterday, Raj Denhoy from Jefferies reiterated a Buy rating on Kamada (NASDAQ: KMDA), with a price target of $7. The company’s shares closed yesterday at $5.45, close to its 52-week high of $6.29.
“KMDA is closing in on a 2017 packed with milestones: inhaled AAT in Europe will be settled; the path forward in the US set; and rabies approved in the US. In the meantime, the company delivered an essentially in-line Q and reiterated its targets for this year and next. The stock remains too cheap at just 1.5x 2017.”
According to TipRanks.com, Denhoy is a 5-star analyst with an average return of 10.6% and a 59.6% success rate. Denhoy covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp., Varian Medical Systems, and Zimmer Biomet Holdings.
Kamada has an analyst consensus of Moderate Buy, with a price target consensus of $8.50.
Perrigo Company (NYSE: PRGO)
“It was good to see PRGO beat expectations/not lower guidance post 3 mixed qtrs. EPS of $1.65 was $0.09 ahead of cons on stronger revs (+$47M) & lower SG&A (-$11M). Mgt made some changes signaling a greater focus on shareholder value including a sale process for Tysabri royalties, a review of the generics business, & adding 2 board members. Can real value be delivered? It won’t be easy.”
According to TipRanks.com, Steinberg is ranked 0 out of 5 stars with an average return of -4.2% and a 38.5% success rate. Steinberg covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Spectrum Pharmaceuticals, and Supernus Pharmaceuticals.
Currently, the analyst consensus on Perrigo Company is Moderate Buy and the average price target is $110, representing a 23.4% upside.
In a report released yesterday, Wells Fargo also reiterated a Hold rating on the stock.
Eli Lilly & Co (NYSE: LLY)
According to TipRanks.com, Holford is a 4-star analyst with an average return of 5.6% and a 55.6% success rate. Holford covers the Healthcare sector, focusing on stocks such as Parnell Pharmaceuticals, Johnson & Johnson, and Sanofi-Aventis Sa.
Currently, the analyst consensus on Eli Lilly & Co is Strong Buy and the average price target is $98.67, representing a 26.0% upside.
In a report issued on November 3, BMO Capital also maintained a Buy rating on the stock with a $91 price target.